Updated: January 25, 2026
What Is Atogepant? Uses, Dosage, and What You Need to Know in 2026
Author
Peter Daggett

Summarize with AI
Everything you need to know about atogepant (Qulipta) in 2026 — what it is, what it treats, how it's taken, and key facts for patients starting this medication.
Atogepant is a newer class of prescription medication that has changed how migraine prevention is approached. If you've been prescribed it or are considering asking your doctor about it, here is everything you need to know in plain English.
What Is Atogepant?
Atogepant is the generic name for Qulipta, a brand-name prescription tablet made by AbbVie. It belongs to a class of drugs called CGRP receptor antagonists — also known as gepants. These drugs block calcitonin gene-related peptide (CGRP), a natural substance in the body that plays a central role in triggering migraine attacks.
Atogepant was first FDA-approved in September 2021 for the preventive treatment of episodic migraine in adults. The FDA expanded the approval in March 2023 to include chronic migraine prevention. It is taken as a once-daily oral tablet — not a rescue medication for when headaches strike, but a preventive that reduces how often they happen.
What Does Atogepant Treat?
Atogepant is FDA-approved for the preventive treatment of migraine in adults. This includes:
- Episodic migraine: 0 to 14 headache days per month. The original approved indication.
- Chronic migraine: 15 or more headache days per month. Expanded indication approved in March 2023.
It is not approved for children. It is not a pain reliever — it won't relieve an active migraine. If you need rescue medication for active migraines, you'll need a separate prescription for that.
How Well Does Atogepant Work?
In the pivotal Phase 3 ADVANCE trial, patients treated with atogepant 60 mg experienced a 4.2-day reduction in monthly migraine days from a baseline of 7.8 days over 12 weeks. Additionally, 56–61% of patients across dose groups achieved a ≥50% reduction in monthly migraine days, compared to 29% of placebo patients. That's a meaningful improvement for patients who've been living with frequent migraines.
What Are the Available Doses?
Atogepant (Qulipta) is available as oral tablets in three strengths:
- 10 mg once daily — used in episodic migraine, or as a reduced dose for certain drug interactions or renal impairment
- 30 mg once daily — intermediate dose for episodic migraine
- 60 mg once daily — standard dose for chronic migraine; often used for severe episodic migraine
Your doctor will prescribe the dose that's right for your migraine frequency and any other medications you take.
How Do You Take Atogepant?
Atogepant is taken as one tablet by mouth once daily, with or without food. Take it at roughly the same time every day. If you miss a dose, take it as soon as you remember — but if it's almost time for your next dose, skip the missed dose and resume your regular schedule. Do not take two doses at once.
Atogepant is a preventive medication — you take it every day regardless of whether you have a headache that day. Most patients see meaningful reduction in migraine frequency within the first month, though full benefit often takes 2–3 months to develop.
Is Atogepant a Controlled Substance?
No. Atogepant is not a controlled substance and has no DEA scheduling. It does not carry a risk of abuse or dependence. You can receive refills on a standard prescription without the special requirements that apply to controlled medications like opioids or stimulants.
What Are the Key Side Effects?
The most common side effects (affecting more than 4% of patients in clinical trials) are nausea, constipation, and fatigue or sleepiness. Decreased appetite and modest weight loss have also been reported. Most side effects are mild and often improve within the first few weeks.
Serious but uncommon side effects include allergic reactions (which can occur days after starting the medication), new or worsening high blood pressure, and Raynaud's phenomenon. Seek emergency care for signs of a severe allergic reaction: swelling of the face/lips/throat, difficulty breathing, or severe hives.
How Much Does Atogepant Cost?
Without insurance, atogepant costs approximately $1,185–$1,600 per month (30-day supply). There is no generic available as of 2026. With the AbbVie Qulipta Complete Savings Card, eligible commercially insured patients can pay as little as $0/month. For more details, see our guide to saving money on atogepant.
How Do I Find Atogepant at a Pharmacy Near Me?
Atogepant is often not stocked at standard retail pharmacies. Use medfinder to check which pharmacies near you have it in stock — medfinder contacts pharmacies on your behalf and texts you the results. Specialty pharmacies (CVS Specialty, Accredo, Walgreens Specialty) are your most reliable in-person option.
Frequently Asked Questions
Atogepant (Qulipta) is used for the preventive treatment of both episodic migraine (0–14 headache days per month) and chronic migraine (15+ headache days per month) in adults. It is not a rescue medication — it's a once-daily tablet taken every day to reduce how often migraines occur.
Atogepant is available in 10 mg, 30 mg, and 60 mg tablets, all taken once daily. The right dose depends on your migraine type, frequency, and other medications you take. For chronic migraine, 60 mg daily is standard. Your doctor will prescribe the appropriate strength based on your situation and any dose adjustments needed for drug interactions or organ impairment.
Many patients see a meaningful reduction in migraine frequency within the first month of taking atogepant. Full benefit often takes 2–3 months to develop. In the pivotal ADVANCE trial, patients experienced a 4.2-day reduction in monthly migraine days after 12 weeks of treatment at the 60 mg dose.
Yes. Atogepant is the generic (chemical) name for the drug, and Qulipta is the brand name made by AbbVie. As of 2026, no generic version of atogepant has been approved — Qulipta is the only available form on the market.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Atogepant also looked for:
More about Atogepant
30,026 have already found their meds with Medfinder.
Start your search today.





